Literature DB >> 9816040

Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.

C Thomssen1, M Schmitt, L Goretzki, P Oppelt, L Pache, P Dettmar, F Jänicke, H Graeff.   

Abstract

The lysosomal cysteine proteases cathepsin B and cathepsin L have been implicated in tumor spread and metastasis. To evaluate the prognostic impact of these proteases for disease-free survival and overall survival in breast cancer, the antigen content of cathepsin B and cathepsin L was determined using ELISA in tumor cytosol fractions of 167 breast cancer patients and in cytosols of 29 benign breast tissue specimens. Median values of 856 ng versus 76 ng cathepsin B/mg protein and of 428 ng versus 56 ng cathepsin L/mg protein were found in tumor versus benign cytosol fractions. A positive correlation between cathepsin B and cathepsin L (r = 0.32, P = 0.0000, Spearman test) was found. Cathepsin L was inversely correlated to hormone receptor status (P = 0.0014, Mann-Whitney U test) and to the presence of tumor necrosis (P = 0.009, Mann-Whitney U test). There were no correlations of cathepsin B or cathepsin L to tumor size, axillary lymph node status, age, menopausal status, tumor grading, and vessel invasion. To perform univariate analyses of disease-free survival, optimal cutoff points were determined by isotonic regression and classification and regression trees analysis. Patients with a high content of cathepsin B (>1092 ng/mg protein) or cathepsin L (>376 ng/mg protein) in their primary tumors had a statistically significantly higher risk of recurrence than patients with a low content of cathepsin B or cathepsin L (5-year disease-free survival: cathepsin B, 70% versus 52%, P = 0.04; cathepsin L, 83% versus 52%, P = 0.0002). Median follow-up was 39 (range, 6-73) months. Multivariate analysis for disease-free survival showed that cathepsin L is a strong and independent prognostic factor with a prognostic impact comparable to that of axillary lymph node status and grading. We conclude that both cathepsin B and cathepsin L may serve as prognostic factors for tumor recurrence in human breast cancer. These data underline the significance of tumor-associated proteolysis for invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9816040

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  32 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

3.  Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L.

Authors:  D Brömme; J L Klaus; K Okamoto; D Rasnick; J T Palmer
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

4.  Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.

Authors:  Dhivya R Sudhan; Christine Pampo; Lori Rice; Dietmar W Siemann
Journal:  Int J Cancer       Date:  2016-02-05       Impact factor: 7.396

5.  Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2013-06-09       Impact factor: 5.150

6.  Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.

Authors:  Qingyong Chen; Jun Fei; Lijun Wu; Zhongyong Jiang; Yuquan Wu; Yun Zheng; Guohua Lu
Journal:  Oncol Lett       Date:  2011-05-11       Impact factor: 2.967

Review 7.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.

Authors:  Oakley C Olson; Johanna A Joyce
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

8.  GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells.

Authors:  Jessica L Schwartz-Roberts; Ayesha N Shajahan; Katherine L Cook; Anni Wärri; Mones Abu-Asab; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2013-02-08       Impact factor: 6.261

Review 9.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

10.  Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.

Authors:  Piyanuch Wonganan; Dharmika S P Lansakara-P; Saijie Zhu; Melisande Holzer; Michael A Sandoval; Mangalika Warthaka; Zhengrong Cui
Journal:  J Control Release       Date:  2013-04-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.